Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462870
2.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Cancer Immunol Immunother
; 70(6): 1583-1592, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231726
3.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474768
4.
DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
Future Oncol
; 15(20): 2349-2360, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28440086
5.
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"
Curr Treat Options Oncol
; 20(3): 23, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30790063
6.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Mediators Inflamm
; 2019: 7652014, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827379
7.
Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?
Future Oncol
; 14(10): 919-926, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29528255
8.
Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study.
J Vasc Interv Radiol
; 28(9): 1234-1239, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28757286
9.
Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!
Eur J Cancer
; 165: 169-173, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35245863
10.
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.
Eur J Cancer
; 153: 260-264, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183225
11.
Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
Lung Cancer
; 152: 1-6, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33310300
12.
Exploring the role of respiratory microbiome in lung cancer: A systematic review.
Crit Rev Oncol Hematol
; 164: 103404, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214609
13.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Clin Lung Cancer
; 22(4): 351-360, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33558194
14.
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
Clin Cancer Res
; 27(24): 6815-6823, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34583970
15.
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.
Vaccines (Basel)
; 9(10)2021 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696233
16.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527756
17.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Cancers (Basel)
; 12(5)2020 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32397295
18.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077515
19.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Clin Lung Cancer
; 21(6): 498-508.e2, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680806
20.
Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Pathol Oncol Res
; 25(2): 513-520, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29557085